• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Thatcher, Nick
    Cerny, T
    Stout, Ronald
    Anderson, Heather
    Barber, Philip V
    Wolstenholme, R J
    Barnes, P
    Deiraniya, A
    Affiliation
    CRC Department of Medical Oncology, Christie Hospital & Holt Radium Institute, Manchester, United Kingdom.
    Issue Date
    1987-11-15
    
    Metadata
    Show full item record
    Abstract
    One hundred sixty-three patients with small cell lung cancer were treated with six courses, at 3-week intervals, of ifosfamide (5 g/m2) with mesna and etoposide. Thoracic radiotherapy was delivered to the limited stage (LS) patients. The complete response rate (CR, determined clinically and radiologically) was 76% for the 78 LS patients with a further 14% partial response (PR). The majority of the CRs were confirmed on a follow-up bronchoscopy. The CR rate was 27% for extensive stage (ES) patients with another 38% undergoing a partial response. The median survival for LS patients was 11 months, (16 months for CR confirmed by rebronchoscopy) and 8 months for ES patients. The 2-year actuarial survival for LS patients is 27%, follow-up ranges from 12 months to 30 months with a median of 22 months. Toxicity was not severe for the patient population, of whom only 20% had a good performance status before chemotherapy. Parental antibiotics were required on 4% of all 844 chemotherapy courses and 12% of courses were delayed due to side effects. The majority of responses occurred within the first two courses of chemotherapy and there was a corresponding improvement in the patients' symptoms and performance status. The regimen produced rapid tumor response with corresponding improvement in symptoms without marked toxicity and allowed further treatment development.
    Citation
    Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer. 1987, 60 (10):2382-7 Cancer
    Journal
    Cancer
    URI
    http://hdl.handle.net/10541/107626
    PubMed ID
    2822217
    Type
    Article
    Language
    en
    ISSN
    0008-543X
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer.
    • Authors: Smith IE, Perren TJ, Ashley SA, Woodiwiss J, Forgeson GV, Yarnold JR, Ford HT
    • Issue date: 1990 May
    • Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy.
    • Authors: Prendiville J, Radford J, Thatcher N, Steward W, Ranson M, Burt P, Stout R
    • Issue date: 1991 Aug
    • Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    • Authors: Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, Schroeder M, Heim M, Dommes M, Mende S
    • Issue date: 1987 Dec
    • Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus.
    • Authors: Thatcher N, Lind M, Stout R, Payne C, Carroll KB, Campbell C, Moussalli H
    • Issue date: 1989 Jul
    • The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer.
    • Authors: Cantwell BM, Bozzino JM, Corris P, Harris AL
    • Issue date: 1988 Feb
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.